Skip to content
value.today

Farallon Biosciences, Inc

🇺🇸 Encinitas, California, USAPharmaceuticalsFounded 2009
Total raised
$104 M
4 rounds on record
Latest round
$50 M
Sep 2012
First round on record
May 2009
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Farallon Biosciences, Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2012$50 MNo. 4$50 to $250 million

Farallon Biosciences, Inc: Raise no. 4, Sep 2012

Investors in this round

9 investors had bought by the notice of Sep 25, 2012: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$50 M of $50 M offered
Smallest investment taken
no minimum stated
What was sold
equity, other: Securities offered consist of convertible preferred stock and the common stock issuable upon conversion of the preferred stock.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Angie A. You · Executive Officer
  • Isan A. Chen · Executive Officer
  • Richard A. Heyman · Executive Officer, Director
  • Brett A. Zbar · Director
  • Carl A. Gordon · Director
  • Carol A. Gallagher · Director
  • Faheem A. Hasnain · Director
  • Leo A. Guthart · Director
  • Peter A. Svennilson · Director
  • Robert A. Adelman · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Richard A. Heyman, Ph.D., President & CEO. Newest notice filed Sep 25, 2012. Read the notice at the SEC.

equitySEC
Feb 2012$38 MNo. 3$10 to $50 million

Farallon Biosciences, Inc: Raise no. 3, Feb 2012

Investors in this round

8 investors had bought by the notice of Aug 2, 2012: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$38 M of $42 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Securities offered consist of convertible preferred stock and the common stock issuable upon conversion of the preferred stock.
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Angie A. You · Executive Officer
  • Isan A. Chen · Executive Officer
  • Richard A. Heyman · Executive Officer, Director
  • Brett A. Zbar · Director
  • Carl A. Gordon · Director
  • Carol A. Gallagher · Director
  • Faheem A. Hasnain · Director
  • Leo A. Guthart · Director
  • Peter A. Svennilson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Richard A. Heyman, Ph.D., President & CEO. Newest notice filed Aug 2, 2012 (1 amendment). Read the notice at the SEC.

equitySEC
Apr 2010$12 MNo. 2$10 to $50 million

Farallon Biosciences, Inc: Raise no. 2, Apr 2010

Investors in this round

4 investors had bought by the notice of Apr 26, 2010: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $22 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Richard A. Heyman · Executive Officer, Director
  • Brett A. Zbar · Director
  • Carl A. Gordon · Director
  • Peter A. Svennilson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Richard A. Heyman, Ph.D., President & Treasurer. Newest notice filed Apr 26, 2010. Read the notice at the SEC.

equitySEC
May 2009$4 MNo. 1$2 to $10 million

Farallon Biosciences, Inc: Raise no. 1, May 2009

Investors in this round

3 investors had bought by the notice of May 27, 2009: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $8 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
  • 46
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in De

People named in the notice

  • Richard A. Heyman · Executive Officer, Director
  • Carl Gordon · Director
  • Peter Svennilson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Richard A. Heyman, Ph.D., President & Treasurer. Newest notice filed May 27, 2009. Read the notice at the SEC.

equitySEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Farallon Biosciences, Inc chose not to state its revenue in its newest notice of a funding round (Sep 2012).

    SEC Form D · Sep 2012

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Sep 2012

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Farallon Biosciences, Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Farallon Biosciences, Inc
NameRoleNamed in
Angie A. YouExecutive officerSep 2012
Isan A. ChenExecutive officerSep 2012
Richard A. HeymanExecutive officerSep 2012
Brett A. ZbarDirectorSep 2012
Carl A. GordonDirectorSep 2012
Carol A. GallagherDirectorSep 2012
Faheem A. HasnainDirectorSep 2012
Leo A. GuthartDirectorSep 2012
Peter A. SvennilsonDirectorSep 2012
Richard A. HeymanDirectorSep 2012
Robert A. AdelmanDirectorSep 2012
Carl GordonDirectorMay 2009
Peter SvennilsonDirectorMay 2009